Company Profile
Kaken Pharmaceutical produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and globally. The company offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis.
Its portfolio also includes Artz, an anti-osteoarthritis agent, Fiblast, a wound-healing agent, Ecclock for the treatment of primary axillary hyperhidrosis, Regroth, a periodontal regenerative agent, Hernicore for the treatment of lumbar disc herniation, and Seprafilm, an adhesion barrier used primarily in surgery and gynecology to reduce complications from post-operative adhesions
Agrochemicals and animal health products, including Polyoxins, that are used as fungicides. Its portfolio also includes Pentoxazone and Metamifop rice herbicides, Salinomycin, an anti-coccidial feed additive for chickens, and Uroston, a urinary stone dissolution and elimination acceleration agent for cattle. Additionally, it is developing KMW-1 for the removal of eschar.
Its portfolio also includes KAR, which is in phase III clinical trial for the treatment of head lice, KP-001, which is in phase III clinical trial for the treatment of refractory vascular malformations, Seladelpar that is in phase III clinical trial for primary biliary cholangitis, KP-483, which is in phase I clinical trial for the treatment of solid tumors, NM26-2198 that is in phase I clinical trial for the treatment of atopic dermatitis, KP-910, which is in phase I clinical trial for peripheral neuropathic pain, and Tildacerfont, which is in phase I clinical trial for congenital adrenal hyperplasia.
It also is involved in the rental of Bunkyo Green Court. The company has a collaboration and licensing agreement with Alumis Inc. to develop, manufacture, and commercialize ESK-001, a selective oral tyrosine kinase 2 (TYK2) inhibitor for dermatology indications in Japan. Founded in 1917, Kaken Pharmaceutical is headquartered in Tokyo, Japan.